These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Plasma fibrinolysis after intraduodenal administration of urokinase in rats. Sumi H, Seiki M, Morimoto N, Tsushima H, Maruyama M, Mihara H. Enzyme; 1985; 33(3):122-7. PubMed ID: 4054071 [Abstract] [Full Text] [Related]
9. [New thrombolytic agents in myocardial infarction]. Charbonnier B, Lang M, Brochier M. Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222 [Abstract] [Full Text] [Related]
10. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy. Collen D. Prog Hemost Thromb; 1986 Nov; 8():1-18. PubMed ID: 3104986 [No Abstract] [Full Text] [Related]
13. Monitoring of fibrinolytic treatment with chromogenic substrate assays. Juhan-Vague I, Aillaud MF, Chiche G. Acta Chir Scand Suppl; 1982 Apr; 509():125-8. PubMed ID: 6962615 [No Abstract] [Full Text] [Related]
14. Potentiation of the thrombolytic efficacy of single-chain urokinase (Pro-urokinase) by heparin. Gulba DC, Fischer K, Reil GH, Daniel WG, Lichtlen PR. Thromb Haemost; 1988 Oct 31; 60(2):350-1. PubMed ID: 3146150 [No Abstract] [Full Text] [Related]
15. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction]. Czyrski J. Wiad Lek; 1989 Apr 01; 42(7):450-2. PubMed ID: 2516932 [Abstract] [Full Text] [Related]
16. [Pharmacological potentials for activating the fibrinolytic system]. Markwardt F. Z Gesamte Inn Med; 1984 May 15; 39(10):209-13. PubMed ID: 6380126 [Abstract] [Full Text] [Related]
17. Plasminogen activators and inhibitor type-1 in alveolar osteitis. Serratì S, Margheri F, Bruschi S, D'Alessio S, Pucci M, Fibbi G, Tonelli P, Del Rosso M. Eur J Oral Sci; 2006 Dec 15; 114(6):500-3. PubMed ID: 17184232 [Abstract] [Full Text] [Related]
19. [Plasminogen activators as thrombolytic agents in myocardial infarction]. Chamone DA, Massumoto C, Fujimura AY, Pileggi F, Bellotti G. Rev Hosp Clin Fac Med Sao Paulo; 1989 Dec 15; 44(6):288-94. PubMed ID: 2518605 [Abstract] [Full Text] [Related]
20. [Role of plasminogen activators in cancer dissemination. Clinical perspectives]. Alonso DF, Bal de Kier Joffé E. Medicina (B Aires); 1992 Dec 15; 52(3):252-6. PubMed ID: 1342692 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]